Co announces results from its ongoing Phase 2 clinical trial of ISIS 301012 in patients with homozygous familial hypercholesterolemia, presented today at the American College of Cardiology Annual Scientific Session. Data were presented for three HoFH patients on concurrent high-dose lipid-lowering therapies. Two patients had completed at least eleven weeks of dosing at 300 mg/week of ISIS 301012 added to ongoing lipid-lowering therapies and experienced at least 50% further reductions in LDL-cholesterol, with similar effects on apoB and other apoB-containing lipoproteins and triglycerides. A third patient had apoB and LDL-C reductions of 29% and 32%, respectively, after just six weeks of dosing. HDL-cholesterol remained stable or increased slightly in these patients. ISIS 301012 was well tolerated in the study. ISIS 301012 has been granted orphan drug status for the treatment of homozygous FH and Isis plans to begin registration-directed studies for FH in 2007. There were no serious adverse events in the study, and ISIS 301012 was well tolerated.